Here are five things to know:
1. Under the private-label agreement, Innovasis will receive Stability Biologics’ private labeled bone allograft tissue products, including its flagship product, Physio.
2. Physio a physiologic bone tissue allograft made of donated human tissue, with no added extrinsic carrier.
3. Innovasis Director of Business Development and Clinical Affairs David Oka said, “We anticipate Physio’s differentiated osteogenic microstructure will provide a potent ecosystem when used with our PEEK-Optima HA Enhanced interbody platform.”
4. Innovasis expects to commercialize its private-labeled product lines by December.
5. Stability Biologics provides human allograft tissue products for spine, orthopedic and wound care applications.
More articles on biologics:
FDA warns biologics company about illegally manufacturing stem cell products: 5 insights
4 things to know about CollPlant
SpinalCyte’s CybroCell injections led to sustained improvement in clinical study: 5 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
